triocean | Adobe Stock
The U.S. Food & Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages 1 through 3 years with a confirmed diagnosis of peanut allergy to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
Palforzia has been approved since January 2020 for initiation of treatment in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy with up-dosing and maintenance in individuals 4 years of age and older.
Those who take Palforzia must continue to avoid peanuts in their diets. A Risk Evaluation and Mitigation Strategy (REMS) is in place for Palforzia to mitigate the risk of anaphylaxis associated with Palforzia, which includes elements to assure safe use.
Latest from Quality Assurance & Food Safety
- 12 TAG Food Safety Consultants Named FSPCA PCHF Version 2 Lead Instructors
- FSIS Announces Stronger Measures to Protect Public from Listeria
- Eagle Product Inspection IPPE 2025 Trade Show
- Dr. Al Baroudi: 'Food Safety Is Not Negotiable'
- USDA Announces Interest in Salmonella Vaccines for Poultry
- Novolyze Releases Free AI FSQ Assistant
- Bio-Rad Receives NF Validation for iQ-Check Listeria spp. and iQ-Check Listeria monocytogenes Shortened Enrichment Protocol
- FDA, Stop Foodborne Illness to Co-Host Food Safety Culture Webinar Series
